Coeptis Capex To Revenue from 2010 to 2024
| COEPW Stock | USD 0.02 0 19.50% |
Capex To Revenue | First Reported 2010-12-31 | Previous Quarter 21 | Current Value 18.66 | Quarterly Volatility 1.30962364 |
Check Coeptis Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coeptis Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 719.4 K, Other Operating Expenses of 41.3 M or Total Operating Expenses of 41.3 M, as well as many indicators such as Price To Sales Ratio of 5.2 K, Dividend Yield of 0.0 or PTB Ratio of 4.43. Coeptis financial statements analysis is a perfect complement when working with Coeptis Therapeutics Valuation or Volatility modules.
Coeptis | Capex To Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.